Cervical Cancer

P2, N=68, Recruiting, University of Utah | Trial primary completion date: Feb 2026 --> Jun 2026

P1, N=149, Enrolling by invitation, Rondo Therapeutics | Recruiting --> Enrolling by invitation

P=N/A, N=15000, Recruiting, The Institute of Molecular and Translational Medicine, Czech Republic | Trial completion date: Dec 2025 --> Dec 2026 | Trial primary completion date: Dec 2025 --> Dec 2026

P=N/A, N=60, Completed, Northwestern University | Trial completion date: Dec 2028 --> Mar 2026 | Trial primary completion date: Dec 2027 --> Dec 2025 | Recruiting --> Completed

By integrating transcriptomics profiling with current clinical testing, clinicians can distinguish transient infections from high-risks lesions likely to progress. This combined approach addresses the critical limitations of morphology and DNA-based methods, enabling more precise therapeutic interventions and reducing unnecessary overtreatment, and the risk of undertreatment or dismissal of high-risk cases.

Current Protocols published by Wiley Periodicals LLC. Basic Protocol 1: Preparation of HeLa cell cultures and treatment with vitamin D3 Basic Protocol 2: Quantification of ROS-positive cells using the Muse Oxidative Stress assay Basic Protocol 3: Measurement of mitochondrial membrane potential using the Muse MitoPotential assay Basic Protocol 4: Ultrastructural evaluation of mitochondrial damage by transmission electron microscopy Basic Protocol 5: Evaluation of lipid damage using a human 8-iso prostaglandin F2α ELISA Basic Protocol 6: Evaluation of total superoxide dismutase activity using an activity assay kit Basic Protocol 7: Evaluation of catalase activity using an activity assay kit Basic Protocol 8: Immunoblot analysis of AKT to assess PI3K/AKT signaling.

P1/2, N=180, Recruiting, Alentis Therapeutics AG

The identified gene signatures may serve as candidates for hypothesis generation and provide a computational framework to prioritize biomarkers and therapeutic targets in cervical cancer. However, these findings are based on in silico analyses and require experimental and clinical validation before translation into practice.

Probe 20b showed concentration- and time-dependent fluorescence in HeLa cells and demonstrated detection performance comparable to DNMT1 antibody with superior nuclear membrane permeability across diverse cell lines. Notably, the relative fluorescence unit ratios of probe 20b to 4',6-diamidino-2'-phenylindole in clinical cervical exfoliated cells showed significant differences among normal cells, low-grade squamous intraepithelial lesion cells, high-grade squamous intraepithelial lesion cells, and cancer cells, indicating its great potential as a tumor diagnostic agent.

It suppressed the expression of Piezo1 in the spinal cord, as well as the levels of CD86, iNOS, IL-6, NF-κB, and p-NF-κB, while promoting the expression of CD206, Arg1, TGF-β, and IL-10. These effects were reversed by treatment with Yoda1, suggesting that electroacupuncture alleviates neuropathic pain in CSR rats by downregulating Piezo1 expression and promoting macrophage polarization toward the M2 phenotype.

P=N/A, N=1103, Completed, The Cleveland Clinic